EP2459533A4 - Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity - Google Patents

Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity

Info

Publication number
EP2459533A4
EP2459533A4 EP10804801A EP10804801A EP2459533A4 EP 2459533 A4 EP2459533 A4 EP 2459533A4 EP 10804801 A EP10804801 A EP 10804801A EP 10804801 A EP10804801 A EP 10804801A EP 2459533 A4 EP2459533 A4 EP 2459533A4
Authority
EP
European Patent Office
Prior art keywords
small molecule
molecule inhibitors
anticancer activity
potential anticancer
carboxyl methyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10804801A
Other languages
German (de)
French (fr)
Other versions
EP2459533A1 (en
Inventor
Jo Lene Leow
Mei-Wang Casey
Patrick J Casey
Mei Lin Go
Kumar Gorla Suresh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG200905128-5A external-priority patent/SG168441A1/en
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of EP2459533A1 publication Critical patent/EP2459533A1/en
Publication of EP2459533A4 publication Critical patent/EP2459533A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
EP10804801A 2009-07-30 2010-07-30 Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity Withdrawn EP2459533A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG200905128-5A SG168441A1 (en) 2009-07-30 2009-07-30 Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
SG200907728 2009-11-20
PCT/SG2010/000286 WO2011014128A1 (en) 2009-07-30 2010-07-30 Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity

Publications (2)

Publication Number Publication Date
EP2459533A1 EP2459533A1 (en) 2012-06-06
EP2459533A4 true EP2459533A4 (en) 2013-01-16

Family

ID=43529562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10804801A Withdrawn EP2459533A4 (en) 2009-07-30 2010-07-30 Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity

Country Status (5)

Country Link
US (1) US8742100B2 (en)
EP (1) EP2459533A4 (en)
CN (1) CN102574787B (en)
SG (1) SG177628A1 (en)
WO (1) WO2011014128A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ES2491390B1 (en) * 2013-02-04 2015-06-22 Universidad Complutense De Madrid NEW INHIBITORS OF ISOPRENYLCISTEINE CARBOXIMETHYLTRANSPHERASE ENZYME (ICMT)
US9216993B2 (en) * 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
TWI743096B (en) 2016-03-16 2021-10-21 美商庫拉腫瘤技術股份有限公司 Bridged bicyclic inhibitors of menin-mll and methods of use
HUE061989T2 (en) 2016-03-16 2023-09-28 Kura Oncology Inc Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AU2018332634A1 (en) * 2017-09-12 2020-04-30 Agency For Science, Technology And Research Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
KR20220166745A (en) * 2021-06-10 2022-12-19 주식회사 아보메드 Novel compound with pendrin inhibitory activity and medical use thereof
CN114133396B (en) * 2022-01-04 2023-07-21 浙江乐普药业股份有限公司 Synthesis method of 8-fluoro-1, 3,4, 5-tetrahydro-azepino [5,4,3-cd ] indol-6-one

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014771A1 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Plc Tryptamine analogues as 5-ht1-like agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
US6800637B2 (en) 2002-09-12 2004-10-05 Wyeth Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
JP4897221B2 (en) * 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド Synthesis of amines and intermediates for their synthesis
DE602004016831D1 (en) * 2003-03-17 2008-11-13 Affinium Pharm Inc PHARMACEUTICAL COMPOSITIONS INHIBITORS OF FAB I AND OTHER ANTIBIOTICS CONTAINED
MX2007006179A (en) * 2004-11-23 2007-06-20 Ptc Therapeutics Inc Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control.
WO2006102126A2 (en) * 2005-03-18 2006-09-28 Duke University Inhibitors of isoprenylcysteine carboxyl methyltransferase
CN101130515B (en) 2006-08-24 2011-06-15 中国科学院上海药物研究所 Substituted-1H- indoles compound, method for preparing the same, application and pharmaceutical composition of the same
AU2008216382A1 (en) * 2007-02-12 2008-08-21 Array Biopharma, Inc. Novel inhibitors hepatitis C virus replication
JP2011511810A (en) * 2008-02-11 2011-04-14 オーガニクス インコーポレイテッド Indole compounds and methods of use thereof
EP2141163A1 (en) 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituted thiazolidinones, their production and utilisation as medicine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014771A1 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Plc Tryptamine analogues as 5-ht1-like agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Kirk-Othmer Encyclopedia of Chemical Technology", 15 September 2006, JOHN WILEY & SONS, INC., article CHARLES S. SELL: "Terpenoids", pages: 1 - 143, XP055045533, DOI: 10.1002/0471238961.2005181602120504.a01.pub2 *
JO LENE LEOW: "Design and synthesis of cysmethynil and analogues as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT)", 13 May 2010 (2010-05-13), Retrieved from the Internet <URL:http://scholarbank.nus.edu.sg/handle/10635/16882?show=full> [retrieved on 20130829] *
LEOW ET AL: "Design and Synthesis of Cysmethynil Analogues as Inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt)", INTERNET CITATION, 1 January 2009 (2009-01-01), pages 1 - 220, XP008151633, Retrieved from the Internet <URL:https://scholarbank.nus.edu.sg/handle/10635/16882> [retrieved on 20120507] *
See also references of WO2011014128A1 *

Also Published As

Publication number Publication date
CN102574787B (en) 2014-12-31
EP2459533A1 (en) 2012-06-06
WO2011014128A1 (en) 2011-02-03
SG177628A1 (en) 2012-03-29
CN102574787A (en) 2012-07-11
US8742100B2 (en) 2014-06-03
US20120197014A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
EP2459533A4 (en) Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
HUS2300018I1 (en) Quinoline-8-sulfonamide derivatives having an anticancer activity
IL221823A (en) Piperidin-4-yl-azetidine derivatives as jak1 inhibitors
EP2391623A4 (en) Inhibitors of akt activity
GB201004179D0 (en) Enzyme inhibitors
HK1177739A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2-
WO2011047384A9 (en) Methods of inhibiting ire1
GB201004178D0 (en) Enzyme inhibitors
EP2413932A4 (en) Inhibitors of akt activity
EP2406250A4 (en) Inhibitors of akt activity
DOP2011000397A (en) NEW DERIVATIVES OF PHENYLIMIDAZOL AS INHIBITORS OF THE ENZYME PDE10A
HK1177208A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors pde10a
AP3342A (en) Imidazole derivatives as PDE10A enzyme inhibitors
EP2405756A4 (en) Inhibitors of akt activity
HK1171013A1 (en) Inhibitors of akt activity akt
PL2506840T3 (en) Uses of hypoxia-inducible factor inhibitors
EP2635287A4 (en) Administration of nedd8-activating enzyme inhibitor
EP2579872A4 (en) Inhibitors of akt activity
HK1189593A1 (en) Imidazole derivatives as pde10a enzyme inhibitors pde10a
EP2513059A4 (en) Inhibitors of akt activity
GB201007392D0 (en) Dynamic tracking
GB201004309D0 (en) New enzyme inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121213

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/24 20060101ALI20121207BHEP

Ipc: A61P 35/00 20060101ALI20121207BHEP

Ipc: A61K 31/4045 20060101ALI20121207BHEP

Ipc: C07D 209/14 20060101AFI20121207BHEP

17Q First examination report despatched

Effective date: 20130906

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150707